Fodder additive for farm animals with enteric coating containing sodium metabisulphite for detoxification of vomitoxin

FIELD: agriculture.

SUBSTANCE: group of inventions relates to a fodder additive and a fodder product for farm animals, in which the particle-nucleus containing sodium metabisulphite and at least one binder has an enteric coating, herewith the thickness and the coating composition protect the sodium metabisulphite from decomposition to sulphur dioxide in an acidic aqueous medium of the stomach.

EFFECT: group of inventions provides delivery of sodium metabisulphite into the lower segments of the gastrointestinal tract as an antidote in case of swallowed vomitoxin by animals.

13 cl, 5 ex, 4 tbl

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: what is presented is a method for acute exposure to organophosphates with pronounced non-anticholinesterase mode of toxicity. A method consists in preventive administration of β-oestradiol 100 mg/kg 20-60 min prior to application of the toxic agent organophosphate.

EFFECT: reducing the manifestations of first signs of the exposure, developing convulsions and complete elimination of animals' death experimentally, administering β-oestradiol 5 days or 1 day before the exposure has not been producing such an effect.

3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to mixed cobalt (II) salts of ketocarboxylic and mercaptocarboxylic acids of general formula (I):

where R=Alk, R'=H, Alk, NH2, NHCOCH3, m=0-3, R"=H, Alk, COOH, n=0-3, where Alk=alkyl C1-C3, or to such compounds as a cobalt (II) salt of mercaptoacetic acid and pyruvic acid, a cobalt (II) salt of mercaptoacetic acid and α-ketoglutaric acid, a cobalt (II) salt of N-acetyl-L-cysteine and pyruvic acid, a cobalt (II) salt of α-ketoglutaric acid and L-cysteine, a cobalt (II) salt of pyruvic acid and 2-mercaptopropionic acid or hydrates or solvates thereof. A method of producing salts of general formula (I) is also disclosed.

EFFECT: invention enables to obtain mixed cobalt (II) salts of ketocarboxylic and mercaptocarboxylic acids, having cyanide antidote activity.

7 cl, 7 ex

FIELD: medicine.

SUBSTANCE: preparation shows an antitoxic activity, and can be used as an antidote for nitrite and nitrate poisoning. A complex compound of 5-hydroxy-6-methyluracil with ascorbic acid (5-hydroxy-6-methyluracil ascorbate) is described by formula: The preparation contains the complex compound in an amount of 0.3-0.4 wt %, and ascorbic acid - the rest. The method for producing the preparation consists in a reaction of 5-hydroxy-6-methyluracil and ascorbic acid taken in the relation of ascorbic acid: 5-hydroxy-6-methyluracil equal to 1:(0.0015-0.0022), in water as a solvent at a temperature of 20-40°C for 30-60 minutes. The complex compound is produced as shown by infra-red and NMR spectra. The antitoxic activity of 5-hydroxy-6-methyluracil on nitrite has been unknown before.

EFFECT: water removal from the reaction mixture under low pressure.

2 cl, 2 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: invention is intended for treatment of acute poisoning of animals with neonicotinoid insecticides. The method comprises intravenous administration of diazepam, Ringer's solution and unitiol.

EFFECT: method improves effectively the survival of animals, reduces the concentration of neonicotinoid insecticides in the body.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology and medicine and concerns the use of dihydrobromide 9-(2-diethylaminoethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole of formula as a biologically active compound possessing high antihypoxic, actoprotective, nootropic activities and having a positive effect on physical efficiency, and a based pharmaceutical composition.

EFFECT: preparing the compound possessing high antihypoxic, actoprotective, nootropic activities and having a positive effect on physical efficiency, and the based pharmaceutical composition.

2 cl, 8 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary science. A detoxicant of polysilicic acid derivatives is specified in a group of reversed-phase sorbents.

EFFECT: using the detoxicant enables practically eliminating toxic effects accompanying animal's poisoning.

2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns veterinary science. A polyfunctional enterosorbent contains schungite-containing minerals comprising silicon dioxide 15.0-70.0 wt %, with an average median particle size 15.0*10-6 m.

EFFECT: invention provides higher efficacy on a wide spectrum of toxic substances, including mycotoxines, nitrates, nitrites, heavy metal salts, and also as an antibacterial and antioxidant agent.

14 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to zinc-containing antidote of lethal and severe poisonings with carbon monoxide. Claimed antidote represents intramolecular tricyclic complex of triethanolamine with zinc salts of inorganic or organic acids (2, 8, 9-trihydrozincatrane) with ratio of triethanolamine to zinc salts being 1:1. Invention also relates to method of protection against poisoning by carbon monoxide by peroral introduction into organism of zinc-containing antidote in 5 vol. % ethanol in dose range 20-60 mg/kg of body weight.

EFFECT: prevention of lethal poisoning with carbon monoxide, higher efficiency and reducing acute toxicity of zinc-containing antidote.

9 cl, 5 ex.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to toxicology, and can be used for treating rats with acute verapamil intoxications. That is ensured by administering sodium thiosulphate 15-20 mg per 100 g of rat's weights as a cardioprotector.

EFFECT: method provides improved central venous pressure value.

3 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to zinc-containing antidote of lethal and severe poisonings with ethanol. Claimed antidote represents intramolecular tricyclic complex of triethanolamine with zinc salts of inorganic or organic acids (2, 8, 9-trihydrozincatran), the ratio of triethanolamine to zinc salts being 1:1. Invention also relates to method of treating ethanol poisoning by introduction into organism of zinc-containing antidote in 5 vol.% ethanol in dose range 30-60 mg/kg of body weight.

EFFECT: prevention of lethal outcome in case of ethanol poisoning and reduction of acute toxicity of zinc-containing antidote.

9 cl, 5 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to capsule for application with inhalator of dry powder, which contains composition in form of dry powder for pulmonary introduction, which contains mechanosynthesised microparticles, consisting of antibiotic and magnesium stearate.

EFFECT: invention relates to method of obtaining claimed capsule and its application in treatment of bacterial infection, associated with certain lungs diseases.

10 cl, 4 ex, 3 tbl, 1 dwg

FIELD: chemistry.

SUBSTANCE: claimed invention relates to biodegradable water-insoluble polyethyleneglycol-based hydrogels. The claimed invention also deals with conjugates of such biodegradable hydrogels with affinity ligands or chelating groups or ion-exchange groups, bound with carriers of prodrugs, in which a biodegradable hydrogel in accordance with the claimed invention is the carrier, and their pharmaceutical compositions, as well as to their application as a drug. Described is a biodegradable water-insoluble poly(ethyleneglycol)-based hydrogel, containing fragments of the main chain, connected by hydrolytically degradable bonds, with fragments of the main chain being characterised by the molecular weight in the range from 1 kDa to 20 kDa and having the structure C*-(A-Hyp)x, where C* represents a branching core, A represents a polymer poly(ethyleneglycol)-based chain, Hyp represents a super-branched dendrite fragment, x represents an integer number from 3 to 15; and where the superbranched dendrite fragment additionally contains reactionable functional groups and connecting functional groups, with the fragments of the main chain being connected together by means of cross-linking fragments, and each cross-linking fragment has at least two hydrolytically degradable bonds at the end. A conjugate and a bound with the carrier prodrug, containing the said biodegradable hydrogel, and the application of the prodrug in a medication are also described. Also described are: a method of obtaining the said hydrogel, which includes a stage (a) reacting of a main chain reagent, and the hydrogel, obtained by the claimed method, in the form of a coating mesh, a stent or a microparticle, obtained by crashing by mechanical methods, such as mixing, breaking, cutting pressing or milling, and sieving in case of necessity.

EFFECT: disclosed are the methods of obtaining the prodrug, the method of obtaining the prodrug, injected through the needle, and the prodrug, obtained by the claimed method.

38 cl, 41 ex, 15 dwg

FIELD: medicine.

SUBSTANCE: what is presented is a method for producing carbonate hydroxyl apatite granules consisting in mixing carbonate hydroxyl apatite powder with aqueous solution of gelatine 5 wt % in ratio of the power 1 g to the solution 7.5 ml until smooth; the produced mixture is dispersed through a capillary of a diameter of 1÷2 mm into vegetable oil cooled down to a temperature of T1=-1÷0°C; the produced granules are decanted from the oil and washed with a mixture of ethanol and acetone in ratio 2:1, dried at a temperature of T2=25÷27°C in the air for t=5÷7 hours to hold a spherical shape. The carbonate hydroxyl apatite granules held their spherical shape within the range of 400-800°C, have a diameter of 1-2 mm, specific surface within the range of 32-0.04 m2/g and mesopore volume within the range of 0-0.098 cm3/g.

EFFECT: maintaining the qualities.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a pharmaceutical composition, which contains formula compound as an active pharmaceutical ingredient or its pharmaceutically acceptable salt; and at least pharmaceutically acceptable filler, where the active pharmaceutical ingredient is present in an amount of at least 80% of the total dry weight of the composition.

EFFECT: composition possesses the good rate of release independently on the pH value.

8 cl, 4 dwg, 7 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, in particular to a pharmaceutical composition in the form of the extrudate, containing at least one pharmaceutically active substance in the form of needles, characterised by the fact that the ratio of the particle size of the needle-like active substance to the diameter of strands constitutes at least 1:25.

EFFECT: invention makes it possible to obtain the more homogeneous extrudate.

11 cl, 13 ex, 10 dwg

FIELD: medicine.

SUBSTANCE: therapeutic agent contains anastrozole, poly(lactic-co-glycolic acid), polyvinyl alcohol and D-mannitol. The therapeutic agent represents sub-micron particles and can be presented in the form of capsules, granules, powder, as well as a suspension for injections.

EFFECT: using the developed therapeutic agent enables achieving the therapeutic effect with lower therapeutic doses and making the antitumour therapy more comfortable for the patient.

2 cl, 1 tbl, 2 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention provides a solid hypolipidemic dosage form containing rosuvastatin or its pharmaceutically acceptable salt in an amount of 3 to 15%, processing additives and a pharmaceutically acceptable excipient containing microcrystalline cellulose, lactose monohydrate, polyvinylpyrrolidone and croscarmellose sodium. The above excipient represents granulate in an amount of 79 to 95 wt % of the dosage form containing absorbed moisture within the range of 0.5% to 1.5%. What is also described is a method for preparing the dosage form.

EFFECT: uniform distribution of the active substance and storage stability of the dosage form of rosuvastatin.

11 cl, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to oral pharmaceutical composition in the form of a granulate produced without spheronisation. The composition contains 92-98 wt % of mesalazine or its pharmaceutically acceptable salt, 2-8 wt % of polyvinylpyrrolidone and an ethylcellulose coating, wherein the above coating weight relates to the above mesalazine weight as 0.3-1.5% and the ethylcellulose coating weight makes 0.11-0.15 mg/cm2. The granulate is packed in a sachet, a capsule or a blister. What is also described is a method for preparing a pharmaceutical composition.

EFFECT: ethylcellulose-coated mesalazine granulate combines a high drug load and a desired mesalazine release profile, namely, 5-25% of released mesalazine 15 min later, 30-70% of released mesalazine 90 min later and 75-100% of released mesalazine 240 min later.

10 cl, 1 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and can be used for producing a controlled-release therapeutic agent containing a modified biologically active agent encapsulated into a polymer, wherein the above modified biologically active agent represents a peptide having an amino acid sequence specified in a group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9. What is also presented is providing the more effective charge of the biological agent, varying an erosion release rate of the biologically active agent, as well as varying the initial diffuse release of the biologically active agent in a polymer-based delivery system.

EFFECT: group of inventions enables changing release kinetics and/or parameters of the drug load of a peptide or a protein encapsulated in the polymer-based delivery systems through the direct variation of an isoelectric point and/or total charge of this peptide without changing the polymer charge.

13 cl, 10 dwg, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of medicine and deals with dry powder-like composition for pulmonary introduction, containing microparticles, including glucagon-like peptide (GLP-1) and pharmaceutically acceptable salt of diketopiperazine (DKP). Said composition can be used as pharmaceutical preparation for treating diseases or states, such as, but not limited by, diabetes, cancer and obesity. Method of obtaining composition and method of introduction are also disclosed.

EFFECT: group of inventions provides stability, long-term efficiency and optimal absorption when introduced into organism.

19 cl, 20 ex, 7 tbl, 31 dwg

FIELD: medicine.

SUBSTANCE: invention represents a dietary supplement for preventing alcoholic intoxication and relieving alcohol withdrawal syndrome presented in the form of a tablet containing silicone dioxide, taurine, succinic acid and excipients; the ingredients in the tablet are taken in certain ratio, in grams.

EFFECT: extending the range for preventing alcoholic intoxication and relieving alcohol withdrawal syndrome.

Up!